Gastric Cancer Market Report and Forecast 2024-2032

Gastric Cancer Market Size

The gastric cancer market was valued at USD 4.7 billion in 2023, driven by growth in clinical trials and research across the 8 major markets. The market is expected to grow at a CAGR of 12.63% during the forecast period of 2024-2032, with the values likely to reach USD 13.8 billion by 2032.

Gastric Cancer Market Outlook

• The increasing prevalence of gastric cancer owing to factors such as the growing aging population and lifestyle-related risks is leading to a higher demand for effective treatments.

• The rising number of clinical trials investigating the efficacy of novel therapies and drug combinations is a significant market trend.

• The growing trend toward personalized medicine and the increasing funding for cancer research is shaping the market landscape.

Gastric Cancer Market Overview

Gastric or stomach cancer refers to a cancerous growth that occurs in the cells lining the stomach. It ranks as the third leading cause of cancer deaths and is estimated to be the fifth most frequently diagnosed cancer . Factors such as aging populations, especially in countries in Japan, and the rising lifestyle-related risks such as diet and smoking are contributing to the growing incidence of gastric cancer, which propels the market demand for effective treatments. The rising development of advanced treatment options like immunotherapies and minimally invasive surgical techniques supports the market growth. Further, the shift towards personalized medicine driven by advancements in genomics and molecular biology is anticipated to influence the market dynamics significantly.

Gastric Cancer Market Growth Drivers

Increasing Prevalence of Gastric Cancer Drives Market Growth

According to the American Cancer  Society, around 26,890 new cases of stomach cancer and approximately 10,880 cases of deaths are estimated to occur in the United States in 2024. Further, stomach cancer is reported to account for 1.5% of all new cancer cases diagnosed in the United States annually. Recent data suggests that older adults are at a high risk of developing stomach cancer, with about 6 in every 10 individuals diagnosed with this cancer falling in the age category of 65 or above. Thus, the substantial burden of gastric cancer along with the increasing aging population is expected to drive the market growth in the coming years.

Gastric Cancer Market Trends

The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:

Shift Toward Personalized Medicine to Affect the Market Landscape Significantly
 
One of the major market trends is the shift towards personalized medicine to treat gastric cancer. This treatment approach is based on the genetic and molecular profile of a patient's tumor, which allows for more precise and effective interventions. In addition, companion diagnostics are increasingly being utilized to decide which patients are most likely to benefit from these targeted treatments. This not only optimizes treatment outcomes but also minimizes unnecessary side effects.

Rise in Investments Poised to Elevate Gastric Cancer Market Value

In July  2024, United Kingdom-based Myricx Bio, a European academic biotech spinout, secured EUR 90 million in a Series A financing round to support the clinical development of novel antibody-drug conjugates (ADCs) treatments for various types of tumors, including gastric cancer. Such substantial investment initiatives to advance gastric cancer treatments are poised to bolster the market growth in the forecast period.

Adoption of Combination Therapies Likely to Boost the Gastric Cancer Market Demand

A significant market trend is the rising preference for combination therapies in the management of gastric cancer. This treatment approach uses multiple therapies (such as chemotherapy, immunotherapy, and targeted drug therapy) either at the same other or sequentially to improve treatment efficacy. As the ongoing research studies and clinical trials continue to indicate improved survival rates and better patient outcomes for combination therapies, their adoption is likely to grow in the market in the forecast period.

Increased Focus on Immunotherapy to Boost Gastric Cancer Market Size

The market is witnessing a growing focus on immunotherapy as a treatment option for gastric cancer, particularly in patients with advanced or metastatic disease. Checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are increasingly being adopted due to their ability to trigger the body's immune system to fight cancer. Moreover, increased research and clinical trials are expected to expand the use of immunotherapy for treating the earlier stages of the disease.

Gastric Cancer Market Segmentation

Market Breakup by Treatment Type

• Chemotherapy

• Immunotherapy

• Surgery

• Targeted Drug Therapy

• Others

Market Breakup by Cancer Type

• Adenocarcinoma

• Gastrointestinal Stromal Tumor

• Carcinoid Tumor

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Others

Market Breakup by End User

• Hospitals & Clinics

• Diagnostic Centers

• Research Laboratories

• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan

• India

Gastric Cancer Market Share
 
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, targeted drug therapy, and others. The chemotherapy segment represents a significant share of the market as this treatment finds its application across various stages of gastric cancer. Chemotherapy is often recommended as a first-line treatment, either alone or in combination with other therapies such as surgery and targeted drug therapy. It can help in shrinking tumors before surgery and also can manage symptoms in advanced stages of cancer and thus, is one of the most commonly utilized treatment options in the market.

Gastric Cancer Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a major market share for gastric cancer, owing to the high prevalence of the disease and advanced healthcare infrastructure. The robust research and development activities directed at finding innovative therapies for gastric cancer further aid the market growth in the region.

 
Additionally, the presence of key pharmaceutical companies and substantial demand for advanced treatment modalities such as immunotherapy and targeted drug therapies contribute to the expansion of the market. Moreover, the increasing investment in cancer research by both the United States government and private sectors is poised to fuel the growth and innovation in the market in the forecast period.

Leading Players in the Gastric Cancer Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca

AstraZeneca, a global research-based biopharmaceutical firm, has a prominent presence in the market. The company boasts a diverese portfolio of oncology drugs that target different aspects of cancer growth and progression. AstraZeneca's human monoclonal antibody Imfinzi (durvalumab)  in combination with chemotherapy is being investigated for its effectiveness in treating gastric cancer.

Pfizer, Inc.

Pfizer, Inc., headquartered in New York, United States, is a major market player focused on expanding its oncology portfolio. The company is actively engaged in exploring innovative treatments that address various cancer types, including gastric cancer. Pfizer has several ongoing clinical trials to investigate the efficacy of new treatment combinations and to expand the indications of its existing oncology drugs.

Novartis AG

Pharmaceutical corporation Novartis AG, based in Basel, Switzerland, is one of the leading companies in the market. The company is investing heavily in developing new therapies for gastric cancer including drugs that target specific molecular pathways involved in cancer growth.

Other key players in the market include Amgen Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Celltrion, AbbVie Inc., and GSK plc.

Key Highlights of the Report

Key Questions Answered in the Gastric Cancer Market Report

• What was the gastric cancer market value in 2023?
• What is the gastric cancer market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• What is the market breakup based on cancer type?
• What is the market breakup by route of administration?
• Who are the major end users in the market?
• What are the major factors aiding the gastric cancer market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How do the prevalence and incidence of gastric cancer affect the market landscape?
• What are the major gastric cancer market trends?
• How does the growth in clinical trials impact the market size?
• Which treatment type will dominate the market share? 
• Which cancer type is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the gastric cancer market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?